CR Boya Bio-pharmaceutical, China Resources Pharmaceutical subsidiary, posts 77.28% drop in H1 net profit attributable to shareholders to RMB 51.19 million

PUBT · 1d ago
CR Boya Bio-pharmaceutical, China Resources Pharmaceutical subsidiary, posts 77.28% drop in H1 net profit attributable to shareholders to RMB 51.19 million
  • China Resources Boya Bio-pharmaceutical, a subsidiary of China Resources Pharmaceutical Group, posted a sharp profit drop in 1H 2026.
  • Revenue fell 36.14% to RMB 643.56 million from RMB 1.01 billion.
  • Net profit attributable to shareholders slid 77.28% to RMB 51.19 million.
  • Net profit excluding extraordinary items declined 89.64% to RMB 17.15 million.
  • Operating cash flow swung to an outflow of RMB 136.31 million from an inflow of RMB 6.95 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260821-12293885), on August 21, 2026, and is solely responsible for the information contained therein.